BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28187757)

  • 1. The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit.
    Bhargava V; Malloy M; Fonseca R
    BMC Pediatr; 2017 Feb; 17(1):50. PubMed ID: 28187757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations.
    Reilly AM; Ding MX; Rower JE; Kiser TH
    J Clin Pharmacol; 2019 Jul; 59(7):997-1005. PubMed ID: 30776089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
    Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
    Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
    Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
    Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin-induced acute kidney injury detected by a prospective pharmacovigilance program from laboratory signals.
    Ramírez E; Jiménez C; Borobia AM; Tong HY; Medrano N; Krauel-Bidwell L; Carcas AJ; Selgas R; Frías J
    Ther Drug Monit; 2013 Jun; 35(3):360-6. PubMed ID: 23666575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the variability and safety of serum trough concentrations of vancomycin in patients admitted to the intensive care unit.
    Qian X; Du G; Weng C; Zhou H; Zhou X
    Int J Infect Dis; 2017 Jul; 60():17-22. PubMed ID: 28457752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose regimen for vancomycin not needing serum peak levels?
    Tan WH; Brown N; Kelsall AW; McClure RJ
    Arch Dis Child Fetal Neonatal Ed; 2002 Nov; 87(3):F214-6. PubMed ID: 12390995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin-associated acute kidney injury in pediatric cardiac intensive care patients.
    Moffett BS; Hilvers PS; Dinh K; Arikan AA; Checchia P; Bronicki R
    Congenit Heart Dis; 2015; 10(1):E6-10. PubMed ID: 24934335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.
    Pritchard L; Baker C; Leggett J; Sehdev P; Brown A; Bayley KB
    Am J Med; 2010 Dec; 123(12):1143-9. PubMed ID: 21183005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of initial vancomycin trough levels and risk factors of vancomycin-induced nephrotoxicity in neonates.
    Dawoud TH; Khan N; Afzal U; Varghese N; Rahmani A; Abu-Sa'da O
    Eur J Hosp Pharm; 2022 Jan; 29(1):44-49. PubMed ID: 34930794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis.
    Horey A; Mergenhagen KA; Mattappallil A
    Ann Pharmacother; 2012 Nov; 46(11):1477-83. PubMed ID: 23073306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Acute Kidney Injury Based on Vancomycin Target Trough Attainment Strategy: Area-Under-the-Curve-Guided Bayesian Software, Nomogram, or Trough-Guided Dosing.
    Knight JM; Iso T; Perez KK; Swan JT; Janak CE; Ikwuagwu JO; Musick WL
    Ann Pharmacother; 2024 Feb; 58(2):110-117. PubMed ID: 37144736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates.
    Constance JE; Balch AH; Stockmann C; Linakis MW; Korgenski EK; Roberts JK; Ward RM; Sherwin CM; Spigarelli MG
    Arch Dis Child Fetal Neonatal Ed; 2016 May; 101(3):F236-43. PubMed ID: 26400103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-Occurring Vancomycin-Associated Acute Kidney Injury in Children Receiving Prolonged Therapy.
    Knoderer CA; Gritzman AL; Nichols KR; Wilson AC
    Ann Pharmacother; 2015 Oct; 49(10):1113-9. PubMed ID: 26160972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized Pharmacokinetic Dosing of Vancomycin Reduces Time to Therapeutic Trough Concentrations in Critically Ill Patients.
    Truong J; Smith SR; Veillette JJ; Forland SC
    J Clin Pharmacol; 2018 Sep; 58(9):1123-1130. PubMed ID: 29957824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
    Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
    Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the vancomycin dosage regimen based on serum creatinine used in the neonatal intensive care unit.
    Irikura M; Fujiyama A; Saita F; Fukushima S; Kitaoka H; Fukuda T; Kawase A; Kondo Y; Ishitsuka Y; Kondo G; Maeda T; Yukawa E; Irie T
    Pediatr Int; 2011 Dec; 53(6):1038-44. PubMed ID: 21810150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis.
    Abdelmessih E; Patel N; Vekaria J; Crovetto B; SanFilippo S; Adams C; Brunetti L
    Pharmacotherapy; 2022 Sep; 42(9):741-753. PubMed ID: 35869689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.